Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HPGD | P15428 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11037564 | 0.77 | HSD17B10 (0.77) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL7011406 | 0.76 | ADORA2A (0.70) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL8974906 | 0.74 | HSD17B10 (0.68) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL5483513 | 0.74 | HSD17B10 (0.72) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL8918577 | 0.74 | ALDH1A1 (0.72) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL28379366 | 0.71 | KDM4E (0.58) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL6256113 | 0.71 | HSD17B10 (0.72) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL3544893 | 0.70 | ADORA2A (0.62) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL935583 | 0.69 | ADORA2A (0.61) | KDM4EHSD17B10ADORA2AHTTADRA2A | |
| SCHEMBL245321 | 0.69 | ADORA2A (0.60) | KDM4EHSD17B10ADORA2AHTTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037779-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | DNPEP, PREP, DPP4 | KDM4E 3785/4885HSD17B10 919/4885ADORA2A 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.